Citizens JMP analyst Constantine Davides initiated coverage of Waystar (WAY) with an Outperform rating and $48 price target The company offers a cloud-based revenue cycle management software platform to more than 30,000 healthcare clients, the analyst tells investors in a research note. The firm sees a strong financial profile for Waystar and views the pending Iodine Software transaction as strategic.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar Holding Corp.: Strategic Innovations and Market Opportunities Justify Buy Rating
- William Blair healthcare services analysts hold analyst/industry conference call
- Waystar Announces Underwriting Agreement with J.P. Morgan
- Waystar 18M share Spot Secondary priced at $39.40
- Waystar 18M share Spot Secondary; price range $39.40-$40.50